With a market capitalization of $5.3 billion, BridgeBio Pharma (BBIO) is a mid-cap biopharmaceutical company that specializes ...

BridgeBio is pointing to the approved indication for Attruby as it gears up to launch the drug with a list price of $18,759 for a 28-day supply, saying it is the only drug with a label that says ...

Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $50 from $45 and keeps an Outperform rating on the shares ...

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking drug, acoramidis (marketed as Attruby), developed ...

The deal – which is worth up to $905 million with an upfront fee of $90 million – gives BMS full control of BridgeBio's experimental SHP2 inhibitor BBP-398, which is already in a phase 1 trial ...

The U.S. FDA approved 10 drugs in November, down from 15 in October, 24 in September and 22 in August. Four new molecular entities were approved by the agency in the month, bringing the year-to-date ...

Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma ... Acoramidis was approved by the FDA on November 22, 2024 as Attruby™, the first and only approved product for adults with ATTR-CM in ...

BridgeBio intends to launch Attruby in the U.S. by the end of 2024. BridgeBio’s pipeline includes numerous candidates in late-stage clinical trials. BBP-418 is another well-known candidate in ...

Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an ...

Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an extensive ...

Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an extensive ...